Syndax Pharmaceuticals Inc (SNDX)
16.10
+0.26
(+1.67%)
USD |
NASDAQ |
Nov 18, 16:00
16.10
0.00 (0.00%)
After-Hours: 20:00
Syndax Pharmaceuticals Normalized PE Ratio
Normalized PE Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Normalized PE Ratio Data
| Date | Value |
|---|---|
| September 29, 2022 | -- |
| September 28, 2022 | -- |
| September 27, 2022 | -- |
| September 26, 2022 | -- |
| September 23, 2022 | -- |
| September 22, 2022 | -- |
| September 21, 2022 | -- |
| September 20, 2022 | -- |
| September 19, 2022 | -- |
| September 16, 2022 | -- |
| September 15, 2022 | -- |
| September 14, 2022 | -- |
| September 13, 2022 | -- |
| September 12, 2022 | -- |
| September 09, 2022 | -- |
| September 08, 2022 | -- |
| September 07, 2022 | -- |
| September 06, 2022 | -- |
| September 02, 2022 | -- |
| September 01, 2022 | -- |
| August 31, 2022 | -- |
| August 30, 2022 | -- |
| August 29, 2022 | -- |
| August 26, 2022 | -- |
| August 25, 2022 | -- |
| Date | Value |
|---|---|
| August 24, 2022 | -- |
| August 23, 2022 | -- |
| August 22, 2022 | -- |
| August 19, 2022 | -- |
| August 18, 2022 | -- |
| August 17, 2022 | -- |
| August 16, 2022 | -- |
| August 15, 2022 | -- |
| August 12, 2022 | -- |
| August 11, 2022 | -- |
| August 10, 2022 | -- |
| August 09, 2022 | -- |
| August 08, 2022 | -- |
| August 05, 2022 | -- |
| August 04, 2022 | -- |
| August 03, 2022 | -- |
| August 02, 2022 | -- |
| August 01, 2022 | -- |
| July 29, 2022 | -- |
| July 28, 2022 | -- |
| July 27, 2022 | -- |
| July 26, 2022 | -- |
| July 25, 2022 | -- |
| July 22, 2022 | -- |
| July 21, 2022 | -- |
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.